Collectively, these findings unveil a previously underappreciated therapeutic axis wherein SGLT2 inhibitors may mitigate anemia-associated risk in AS through mechanisms distinct from volume contraction or hemoconcentration, with potential implications for improving myocardial oxygenation and delaying decompensation in this high-risk population. The gene discussed is SLC5A2; the disease is aortic stenosis.